

E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

Safety and Efficacy of FCM in the Management of Iron Deficiency Anaemia: A Multi-Centre Cohort-Based Study

Poulami Gupta Banerjee¹, Utpalendu Banerjee², Manoj Mukhopadhyay³, Prabhu Shanmugam⁴, Kumari Lily⁵

^{1,2,3,4,5}West Bengal Chemical Industries

Abstract:

This study investigated the efficacy and safety of ferric carboxymaltose (FCM) in the treatment of iron deficiency anaemia (IDA) in a cohort of 100 patients across four locations in West Bengal, India. The results demonstrated significant improvements in various hematological parameters, including a substantial increase in haemoglobin levels, following FCM administration. The study also highlighted the absence of adverse events, showcasing a favorable safety profile of FCM in this population.

The use of FCM, a third-generation parenteral iron formulation, proved effective in addressing moderateto-severe IDA, aligning with existing evidence supporting its efficacy and safety. The rapid and substantial improvement in haemoglobin levels observed within four weeks of FCM administration emphasizes its efficiency in iron repletion, particularly in cases where oral preparations may be insufficient. The absence of adverse effects further supports the tolerability of FCM, a crucial factor in its consideration for widespread use.

The study contributes valuable real-world data, especially in the context of the high prevalence of anaemia in India. The findings underscore the potential of FCM as a cornerstone in the treatment of severe anaemia, advocating for its inclusion in targeted interventions and public health initiatives. Overall, this study adds to the growing body of evidence supporting FCM as a promising option in the management of iron deficiency anaemia.

Keywords: Iron Deficiency Anaemia, Ferric Carboxymaltose, Safety, Efficacy

1. Introduction

Anaemia stands as a pervasive global public health concern, impacting around one-third (22.8%) of the global population in the year 2019.¹ The 2019–2020 National Family Health Survey (NFHS-5) data reveals a significant prevalence of anaemia in India, where 57% of women and 25% of men between the ages of 15 and 49 exhibit this health condition.¹ These statistics emphasising the urgency of targeted interventions and public health initiatives to address this critical health issue.¹ Moreover, the persistence of severe anaemia remains a significant challenge, delineated by haemoglobin (Hb) levels falling below 7 g/dL, despite the existence of Indian guidelines and dedicated efforts aimed at eradicating anaemia.¹ This underscores the need for a more targeted approach in addressing severe form of the disease.¹



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

Iron deficiency anaemia (IDA) stands out as the predominant cause of anaemia, with iron supplementation being the principal mode of treatment.² This supplementation may take the form of either oral or parenteral administration.¹⁻² Oral preparations prove insufficient in cases of moderate-to-severe anaemia, where a swift elevation of haemoglobin levels and replenishment of iron stores is imperative.¹⁻² Consequently, parenteral iron preparations emerge as the cornerstone of treatment for moderate-to-severe anaemia, offering a more effective and expedited means of addressing the condition.¹⁻² However, both oral and parenteral iron preparations have their side effects; thus, newer intravenous (IV) iron formulations with a favourable adverse events profile as compared to traditional parenteral iron products have been developed by Eskag Pharma Pvt Ltd.

Ferric carboxymaltose (FCM), a third-generation parenteral iron formulation designed by Eskag Pharma Pvt Ltd could overcome the limitations of existing parenteral iron preparations. FCM, a novel non-dextran IV iron agent, had a very low immunogenic potential and thus predisposed no anaphylactic reactions to any of the participants. Its properties permitted the administration of large dosages (1000 mg/infusion) in a single session (15-minute infusion) without the necessity of a test dose.

2. Materials and methods

2.1. Study design

This was a multicentre, cohort-based, observational, data collection study involving four Eskag Sanjeevani hospitals of West Bengal, India. A cohort of 100 human subjects was enrolled from four distinct centres: Basirhat (location 1), Behala (location 2), ID & BG (location 3), and Howrah (location 4). In the course of the ten-month study, commencing in June 2022 and concluding in March 2023, all participants received intravenous ferric carboxymaltose (FCM) in a diluted form (100 ml normal saline). At the commencement of the study, patient-specific information, encompassing their identities, haemoglobin levels, and batch numbers, were meticulously documented.

2.2. Patient details

Patients details along with their haemoglobin levels were recorded before administration of FCM. Other vitals, encompassing oxygen saturation, blood pressure, body temperature, pulse rate, vision, taste, anaphylactic shock, respiratory problems, and restlessness were documented as well. these are mentioned below:

SL. NO.	DATE	TIME	PROCESS OF DOSAGE	AMOUNT OF FCM	PATIENT'S NAME	Hb.
1	06-04- 2022	06:15:00 PM	DIALUTED IN 100 ml Ns	2 ml	KALIPADA SARKAR	9.7
2	06-04- 2022	02:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	GOPAL SARDAR	9.2
3	06-04- 2022	06:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	TILAK KR SARKAR	9.1
4	07-04- 2022	10:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	HASANUR JAMAL MOLLA	8
5	09-04- 2022	10:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	BIDYUT DEY	7.5



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> •

• Email: editor@ijfmr.com

2022 PM ml Ns Amil Ns<	l Ns2 mlARIF BILLA9.5TED IN 100 l Ns2 mlMARJINA BIBI8.3TED IN 100 l Ns2 mlSANTOSH MONDAL8.4TED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7TED IN 100 l Ns2 mlAKBAR MONDAL7.9	PM
7 09-04- 2022 10:00:00 PM DIALUTED IN 100 ml Ns 2 ml MARJINA BIBI 8. 8 09-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SANTOSH MONDAL 8. 9 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml HABBIBUL ISLAM SK 8. 10 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 11 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 11 11-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7. 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7. 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7. 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7. 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	YED IN 100 l Ns2 mlMARJINA BIBI8.3YED IN 100 l Ns2 mlSANTOSH MONDAL8.4YED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7YED IN 100 l Ns2 mlAKBAR MONDAL7.9	
7 2022 PM ml Ns 2 ml MARJINA BIBI 8. 8 09-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SANTOSH MONDAL 8. 9 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml HABBIBUL ISLAM SK 8. 10 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 11 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 11 11-04- 2022 10:00:00 DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7. 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7. 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7. 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8. 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7. 16<	I Ns2 mlMARJINA BIBI8.3TED IN 100 l Ns2 mlSANTOSH MONDAL8.4TED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7TED IN 100 l Ns2 mlAKBAR MONDAL7.9	10.00.00
8 09-04- 2022 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml SANTOSH MONDAL 8. 9 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml HABBIBUL ISLAM SK 8. 10 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 10 2022 AM ml Ns 2 ml AKBAR MONDAL 7. 11 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7. 11 2022 AM ml Ns 2 ml GIYAS MONDAL 7. 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7. 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7. 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8. 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7. 16 14-04- 2	TED IN 100 l Ns2 mlSANTOSH MONDAL8.4TED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7TED IN 100 l Ns2 mlAKBAR MONDAL7.9	
8 2022 PM ml Ns 2 ml MONDAL 8. 9 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml HABBIBUL ISLAM SK 8.' 10 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7.' 11 11-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7.' 11 2022 AM ml Ns 2 ml TUSA MONDAL 7.' 11 2022 AM ml Ns 2 ml GIYAS MONDAL 7.' 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7.' 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.' 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.' 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.' 16 14-04- 2022 02:00:00 </td <td>l Ns2 mlMONDAL8.4YED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7YED IN 100 l Ns2 mlAKBAR MONDAL7.9</td> <td></td>	l Ns2 mlMONDAL8.4YED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7YED IN 100 l Ns2 mlAKBAR MONDAL7.9	
9 10-04- 2022 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml HABBIBUL ISLAM SK 8.5 10 10-04- 2022 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7.5 11 10-04- 2022 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7.5 11 11-04- 2022 10:00:00 AM DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7.5 12 11-04- 2022 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7.5 13 12-04- 2022 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.5 14 12-04- 2022 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.5 15 12-04- 2022 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.5 16 14-04- 2022 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 14-04- 2022 PM ml Ns 2 ml SAHIDA BIBI 8 <td>TED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7TED IN 100 l Ns2 mlAKBAR MONDAL7.9</td> <td></td>	TED IN 100 l Ns2 mlHABBIBUL ISLAM SK8.7TED IN 100 l Ns2 mlAKBAR MONDAL7.9	
9 2022 AM ml Ns 2 ml SK 8. 10 10-04- 2022 09:45:00 DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7. 11 11-04- 2022 10:00:00 DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7. 11 2022 AM ml Ns 2 ml TUSA MONDAL 7. 12 2022 AM ml Ns 2 ml GIYAS MONDAL 7. 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7. 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.4 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.4 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 200:00:00 DIALUTED IN 100	l Ns2 mlSK8.7YED IN 100 l Ns2 mlAKBAR MONDAL7.9YED IN 100100100100	
10 10-04- 2022 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml AKBAR MONDAL 7.3 11 11-04- 2022 10:00:00 DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.4 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.4 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 14-04- 06:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8	TED IN 100 l Ns2 mlAKBAR MONDAL7.9TED IN 1007.9	
10 2022 AM ml Ns 2 ml AKBAR MONDAL 7.3 11 11-04- 2022 10:00:00 DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7 12 2022 AM ml Ns 2 ml GIYAS MONDAL 7 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.3 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.3 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.3 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.3 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8 14-04- 06:00:00	l Ns 2 ml AKBAR MONDAL 7.9	
11 11-04- 2022 10:00:00 AM DIALUTED IN 100 ml Ns 2 ml TUSA MONDAL 7 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7.4 12 11-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7.4 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.4 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.4 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	FD IN 100	
11 2022 AM ml Ns 2 ml TUSA MONDAL 7 12 11-04- 06:00:00 DIALUTED IN 100 2 ml GIYAS MONDAL 7.4 12 2022 PM ml Ns 2 ml GIYAS MONDAL 7.4 13 12-04- 06:00:00 DIALUTED IN 100 2 ml SWAPNA DAS 7.4 14 12-04- 02:00:00 DIALUTED IN 100 2 ml NAMITA KUNDU 8.4 14 12-04- 02:00:00 DIALUTED IN 100 2 ml NAMITA KUNDU 8.4 15 12-04- 06:00:00 DIALUTED IN 100 2 ml HASNA BANU 7.4 16 14-04- 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8 16 14-04- 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8		
12 11-04- 2022 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml GIYAS MONDAL 7.4 13 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.4 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 14 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.4 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	2 ml TUSA MONDAL 7	
12 2022 PM ml Ns 2 ml GIYAS MONDAL 7.3 13 12-04- 06:00:00 DIALUTED IN 100 2 ml SWAPNA DAS 7.3 14 12-04- 02:00:00 DIALUTED IN 100 2 ml NAMITA KUNDU 8.4 14 12-04- 02:00:00 DIALUTED IN 100 2 ml NAMITA KUNDU 8.4 15 12-04- 06:00:00 DIALUTED IN 100 2 ml HASNA BANU 7.4 15 12-04- 06:00:00 DIALUTED IN 100 2 ml HASNA BANU 7.4 16 14-04- 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8 14-04- 06:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8	ED IN 100	
13 12-04- 2022 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml SWAPNA DAS 7.3 14 12-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.5 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	2 ml GIYAS MONDAL 7.4	
13 2022 PM ml Ns 2 ml SWAPNA DAS 7.3 14 12-04- 02:00:00 DIALUTED IN 100 2 ml NAMITA KUNDU 8.4 14 2022 PM ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 06:00:00 DIALUTED IN 100 2 ml HASNA BANU 7.5 16 14-04- 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8 16 14-04- 06:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8	'ED IN 100	
14 12-04- 2022 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.5 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	2 ml SWAPNA DAS 7.8	
14 2022 PM ml Ns 2 ml NAMITA KUNDU 8.4 15 12-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.9 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	ED IN 100	
15 12-04- 2022 06:00:00 AM DIALUTED IN 100 ml Ns 2 ml HASNA BANU 7.9 16 14-04- 2022 02:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 16 14-04- 2022 06:00:00 DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8	2 ml NAMITA KUNDU 8.4	
15 2022 AM ml Ns 2 ml HASNA BANU 7.9 16 14-04- 02:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8 16 2022 PM ml Ns 2 ml SAHIDA BIBI 8 14-04- 06:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8	ED IN 100	
16 14-04- 2022 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml SAHIDA BIBI 8 14-04- 06:00:00 DIALUTED IN 100 2 ml SAHIDA BIBI 8	2 ml HASNA BANU 7.9	
16 2022 PM ml Ns 2 ml SAHIDA BIBI 8 14-04- 06:00:00 DIALUTED IN 100 6 <td< td=""><td>'ED IN 100</td><td></td></td<>	'ED IN 100	
14-04- 06:00:00 DIALUTED IN 100	2 ml SAHIDA BIBI 8	
17	ED IN 100	
17 2022 AM ml Ns 2 ml DAI I MISTI KI 3.	l Ns 2 ml BAPI MISTTRI 8.6	AM
14-04- 12:00:00 DIALUTED IN 100	ED IN 100	12:00:00
182022AMDifficience2 mlSANTANU DAS7.5	l Ns 2 ml SANTANU DAS 7.8	AM
15-04- 02:30:00 DIALUTED IN 100	TED IN 100	
1910 0402.00.00DIFILCTILD IN 1002 mlPRITIKA DAS8.3192022PMml Ns2 mlPRITIKA DAS8.3	l Ns 2 ml PRITIKA DAS 8.5	PM
16-04- 02:00:00 DIALUTED IN 100	TED IN 100 Image: Comparison of the second sec	02:00:00
2010 010210000Diffic fills in 1002 mlABID HOSSIAN72022PMml Ns2 mlABID HOSSIAN7	l Ns 2 ml ABID HOSSIAN 7	PM
20-04- 06:00:00 DIALUTED IN 100	TED IN 100 SAIFULLA	06:00:00
2120 0400.0000Difficulty introduct2 mlMillion Chain8.92022PMml Ns2 mlMONDAL8.9	l Ns 2 ml MONDAL 8.9	PM
21-04- 10:00:00 DIALUTED IN 100 A KBAR ALI	YED IN 100 AKBAR ALI	10:00:00
$\begin{bmatrix} 22 \\ 2022 \end{bmatrix} \begin{array}{c} AM \\ M \end{bmatrix} \begin{array}{c} DM B \\ M $	l Ns 2 ml MONDAL 9.9	AM
22-04- 02:00:00 DIALUTED IN 100 BISWANATH		02:00:00
$\begin{bmatrix} 23 \\ 2022 \end{bmatrix} PM \qquad \text{ml Ns} \qquad 2 \text{ ml} \qquad BISWAS \qquad 8.3$	'ED IN 100 BISWANATH	PM
24 19-05- 02:00:00 DIALUTED IN 100 2 1 CODAL DISWAS	2 ml 8.5	02:00:00
2410 000210000Difficulture2 mlGOPAL BISWAS92022PMml Ns2 mlGOPAL BISWAS9	l Ns 2 ml BISWAS 8.5	PM
25 21-05- 12:00:00 DIALUTED IN 100 ARAFAT	l Ns2 mlBISWAS8.5TED IN 1002 mlGOPAL BISWAS9	
$\begin{bmatrix} 25 & 2022 \\ 2022 & AM \\ \end{bmatrix} \begin{array}{c} 12.00.00 \\ ml Ns \\ \end{bmatrix} \begin{array}{c} 12.00.00 \\ 2 \\ ml \\ \end{bmatrix} \begin{array}{c} 1110 \\ 2 \\ ml \\ \end{bmatrix} \begin{array}{c} 1110 \\ DAFADAR \\ \end{bmatrix} \begin{array}{c} 7.10 \\ 7.10 \\ Table \\ T$	l Ns2 mlBISWAS8.5YED IN 100 l Ns2 mlGOPAL BISWAS9YED IN 100ARAFAT	12:00:00

Table 1: Patient details of Location 1 (Basirhat, West Bengal)



E-ISSN: 2582-2160 • Website: www.ijfmr.com • Email: editor@ijfmr.com

DATE	TIME	PROCESS OF DOSAGE	AMOUNT OF FCM	PATIENT'S NAME	Hb.
04.06	10.00.00		OFFCM		
			2 ml		7
				ANIAN	
			2 ml	REHANA BIBI	7.5
				S A MDUI IN A TU	
			2 ml		8.5
				DIAKA	
			2 ml	BASUDEB TUNG	7.4
			2 ml	JHARNA DAS	8.7
			2 ml	JYOTSNA DUTTA	8
			2 ml	RAJA DHANUK	9.7
			2 ml	RAJIA BIBI	8.5
			2 ml		9.5
				MONDAL	
			2 ml	LALAN ROY	7.8
			2 ml ALPANA DAS	8.6	
			2 ml	BINOD MONDAL	9.9
2022	AM	ml Ns			,,,
15-06-	12:00:00	DIALUTED IN 100	2 ml	DEB KUMAR	7.5
2022	AM	ml Ns	2 111	TIWARI	1.0
21-06-	02:00:00	DIALUTED IN 100	2 ml SOMA DUTTA	SOMA DUTTA	9
2022	PM	ml Ns	2 111	Source De l'Int	
22-06-	10:00:00	DIALUTED IN 100	2 ml	SOUMEN PAUL	8.3
2022	PM	ml Ns	2 111	SOUMENTAUL	0.5
25-06-	12:00:00	DIALUTED IN 100	2 ml	DILIP	7.8
2022	AM	ml Ns	2 1111	CHOWDHURY	7.0
08-07-	02:00:00	DIALUTED IN 100	2 ml	CITA DANI IANA	9.2
2022	PM	ml Ns	2 1111	GIIA KANI JANA	9.2
27-07-	02:00:00	DIALUTED IN 100	21	ASFAR ALI	04
2022	PM	ml Ns	2 mi	MOLLA	8.4
21-08-	02:00:00	DIALUTED IN 100	3 1	ASUTOSH	_
2022	PM	ml Ns	2 ml	THAKUR	7
22-08-	06:00:00	DIALUTED IN 100			0.1
2022	PM	ml Ns	2 ml	TASIR ALI KHAN	9.1
	2022 21-06- 2022 22-06- 2022 25-06- 2022 08-07- 2022 27-07- 2022 21-08- 2022 21-08- 2022	2022AM07-06-10:00:002022AM07-06-02:00:002022PM08-06-06:00:002022PM08-06-09:45:002022PM08-06-02:00:002022PM08-06-02:30:002022PM08-06-02:30:002022PM13-06-02:00:002022PM13-06-06:00:002022PM13-06-06:00:002022PM14-06-10:00:002022AM15-06-12:00:002022AM21-06-10:00:002022PM25-06-10:00:002022PM25-06-10:00:002022PM25-06-12:00:002022PM25-06-10:00:002022PM25-06-12:00:002022PM25-06-12:00:002022PM25-06-12:00:002022PM25-06-10:00:002022PM25-06-12:00:002022PM21-08-02:00:002022PM21-08-02:00:002022PM21-08-06:00:00	04-06- 10:00:00 DIALUTED IN 100 2022 AM ml Ns 07-06- 10:00:00 DIALUTED IN 100 2022 AM ml Ns 07-06- 02:00:00 DIALUTED IN 100 2022 PM ml Ns 07-06- 02:00:00 DIALUTED IN 100 2022 PM ml Ns 08-06- 06:00:00 DIALUTED IN 100 2022 AM ml Ns 08-06- 09:45:00 DIALUTED IN 100 2022 PM ml Ns 08-06- 02:00:00 DIALUTED IN 100 2022 PM ml Ns 08-06- 02:30:00 DIALUTED IN 100 2022 PM ml Ns 13-06- 02:00:00 DIALUTED IN 100 2022 PM ml Ns 13-06- 06:00:00 DIALUTED IN 100 2022 PM ml Ns 14-06- 10:00:00 DIALUTED IN 100 2022 AM ml Ns <td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td> <td>04-06- 202210:00:00 AMDIALUTED IN 100 ml Ns2 mlSK SAMIM AKTAR07-06- 202210:00:00 AMDIALUTED IN 100 ml Ns2 mlREHANA BIBI07-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlSAMBHUNATH DHARA08-06- 202206:00:00 PMDIALUTED IN 100 ml Ns2 mlBASUDEB TUNG2022PMml Ns2 mlJHARNA DAS08-06- 202209:45:00 PMDIALUTED IN 100 ml Ns2 mlJYOTSNA DUTTA08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlJYOTSNA DUTTA08-06- 202206:15:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA ADAS13-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlALPANA DAS14-06- 202206:00:00 PMDIALUTED IN 100 ml Ns2 mlBINOD MONDAL15-06- 202212:00:00 PMDIALUTED IN 100 ml Ns2 mlSOMA DUTTA2022 2022PM PMml Ns2 mlSOMA DUTTA2022 2022PM PMml Ns2 mlGITA RANI JANA2022 2022PM PMml Ns2 mlGITA RANI JANA21-06- 2020DIAL</td>	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	04-06- 202210:00:00 AMDIALUTED IN 100 ml Ns2 mlSK SAMIM AKTAR07-06- 202210:00:00 AMDIALUTED IN 100 ml Ns2 mlREHANA BIBI07-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlSAMBHUNATH DHARA08-06- 202206:00:00 PMDIALUTED IN 100 ml Ns2 mlBASUDEB TUNG2022PMml Ns2 mlJHARNA DAS08-06- 202209:45:00 PMDIALUTED IN 100 ml Ns2 mlJYOTSNA DUTTA08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlJYOTSNA DUTTA08-06- 202206:15:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA DHANUK08-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlRAJA ADAS13-06- 202202:00:00 PMDIALUTED IN 100 ml Ns2 mlALPANA DAS14-06- 202206:00:00 PMDIALUTED IN 100 ml Ns2 mlBINOD MONDAL15-06- 202212:00:00 PMDIALUTED IN 100 ml Ns2 mlSOMA DUTTA2022 2022PM PMml Ns2 mlSOMA DUTTA2022 2022PM PMml Ns2 mlGITA RANI JANA2022 2022PM PMml Ns2 mlGITA RANI JANA21-06- 2020DIAL



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

21	04-09- 2022	09:45:00 AM	DIALUTED IN 100 ml Ns	2 ml	SUSANTA MUKHERJEE	7.9
22	09-09- 2022	02:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	DIPAK KUMAR DAS	8.4
23	14-09- 2022	06:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	ARUP DOLUI	8.9
24	27-09- 2022	06:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	YEASMINA BIBI	7.9
25	16-10- 2022	10:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	FULJAN BIBI	8

 Table 2: Patient details of Location 2 (Behala, West Bengal)

NO. DATE TIME DOSAGE OF FCM PATIENT'S NAME Hb. 1 01-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml BHOLA MAHATO 9.5 2 02-02- 2023 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml RUPESH KR. ROY 8.7 3 02-02- 2023 12:00:00 AM DIALUTED IN 100 ml Ns 2 ml RAJA BASU 7.8 4 03-02- 2023 12:00:00 AM DIALUTED IN 100 ml Ns 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 2023 06:00:00 DIALUTED IN 100 2023 2 ml MILAN BISWAS 9.7 6 05-02- 2023 06:15:00 PM DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 8 08-02- 2023 PM ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA MALIK 8.4 11 <th>SL.</th> <th></th> <th></th> <th>PROCESS OF</th> <th>AMOUNT</th> <th></th> <th></th>	SL.			PROCESS OF	AMOUNT		
1 01-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml BHOLA MAHATO 9.5 2 02-02- 2023 09:45:00 AM DIALUTED IN 100 ml Ns 2 ml RUPESH KR. ROY 8.7 3 02-02- 2023 12:00:00 AM DIALUTED IN 100 ml Ns 2 ml RAJA BASU 7.8 4 03-02- 2023 12:00:00 AM DIALUTED IN 100 ml Ns 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 06:00:00 DIALUTED IN 100 DIALUTED IN 100 2023 2 ml SHIB SANKAR MONDAL 8.6 6 05-02- 2023 06:05:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA MALIK		DATE	TIME			PATIENT'S NAME	Hb.
1 2023 PM ml Ns 2 ml BHOLA MAHATO 9.5 2 02-02- 2023 09:45:00 DIALUTED IN 100 ml Ns 2 ml RUPESH KR. ROY 8.7 3 02-02- 2023 12:00:00 DIALUTED IN 100 Ml Ns 2 ml RAJA BASU 7.8 4 03-02- 2023 12:00:00 DIALUTED IN 100 AM 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 2023 06:00:00 DIALUTED IN 100 AM 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 PM ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 2 ml 2 ml BECHAN SAHA 8.4 11 10-0	110.	01-02-	02.00.00				
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1				2 ml	BHOLA MAHATO	9.5
2 2023 AM ml Ns 2 ml RUPESH KR. ROY 8.7 3 02-02- 2023 12:00:00 DIALUTED IN 100 ml Ns 2 ml RAJA BASU 7.8 4 03-02- 2023 12:00:00 DIALUTED IN 100 ml Ns 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITAN BISWAS 9.7 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 8.4 11 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.9							
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2				2 ml	RUPESH KR. ROY	8.7
3 2023 AM ml Ns 2 ml RAJA BASU 7.8 4 03-02- 2023 12:00:00 DIALUTED IN 100 ml Ns 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHN BISWAS 9.7 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 AM ml Ns 2 ml ABEDA BIBI 9.1 13							
4 03-02- 2023 12:00:00 AM DIALUTED IN 100 ml Ns 2 ml SHIB SANKAR MALAKAR 7.5 5 04-02- 2023 06:00:00 AM DIALUTED IN 100 ml Ns 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 PM DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml MITAN BISWAS 9.7 7 05-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 8 08-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 AM ml Ns 2 ml ABEDA BIBI 9.9 12 10-02- 2023 PM ml Ns 2 ml ABEDA BIBI 9.1 <tr< td=""><td>3</td><td></td><td></td><td></td><td>2 ml</td><td>RAJA BASU</td><td>7.8</td></tr<>	3				2 ml	RAJA BASU	7.8
4 2023 AM ml Ns 2 ml MALAKAR 7.5 5 04-02- 2023 06:00:00 AM DIALUTED IN 100 ml Ns 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 PM DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 PM ml Ns 2 ml SMRITI DHALI 8 14 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>SHID SANKAD</td><td></td></t<>						SHID SANKAD	
5 04-02- 2023 06:00:00 AM DIALUTED IN 100 ml Ns 2 ml SANDHYA MONDAL 8.6 6 05-02- 2023 06:15:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml NITTISH KR. MONDAL 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 AM ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 AM ml Ns 2 ml SMRITI DHALI 8 14<	4				2 ml		7.5
5 2023 AM ml Ns 2 ml MONDAL 8.6 6 05-02- 06:15:00 DIALUTED IN 100 2 ml MILAN BISWAS 9.7 7 05-02- 02:00:00 DIALUTED IN 100 2 ml MILAN BISWAS 9.7 7 05-02- 02:00:00 DIALUTED IN 100 2 ml NITISH KR. 8.5 8 08-02- 02:00:00 DIALUTED IN 100 2 ml MITHU PODDER 8.5 9 09-02- 06:00:00 DIALUTED IN 100 2 ml SEKHAR MAJHI 7.8 10 09-02- 06:00:00 DIALUTED IN 100 2 ml BECHAN SAHA 8.4 11 10-02- 02:00:00 DIALUTED IN 100 2 ml HARAPRASAD 9.9 12 10-02- 06:00:00 DIALUTED IN 100 2 ml ABEDA BIBI 9.1 13 12-02- 10:00:00 DIALUTED IN 100 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 2 ml							
6 05-02- 2023 06:15:00 PM DIALUTED IN 100 ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml NITISH KR. MONDAL 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 0IALUTED IN 100 DIALUTED IN 100 2 ml BHABAT TURI 8.5 </td <td>5</td> <td></td> <td></td> <td></td> <td>2 ml</td> <td></td> <td>8.6</td>	5				2 ml		8.6
6 2023 PM ml Ns 2 ml MILAN BISWAS 9.7 7 05-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml NITISH KR. MONDAL 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 AM ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8.5						MONDAL	
7 05-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml NITISH KR. MONDAL 8.5 8 08-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 10 09-02- 2023 02:00:00 PM DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 10:00:00 AM DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8.5	6				2 ml	MILAN BISWAS	9.7
7 2023 PM ml Ns 2 ml MONDAL 8.5 8 08-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 13 12-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8.5							
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	7				2 ml		8.5
8 2023 PM ml Ns 2 ml MITHU PODDER 8.5 9 09-02- 2023 06:00:00 PM DIALUTED IN 100 ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 10 2023 PM ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 AM ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8.5						MONDAL	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	8				2 ml	MITHU PODDER	8.5
9 2023 PM ml Ns 2 ml SEKHAR MAJHI 7.8 10 09-02- 2023 02:00:00 DIALUTED IN 100 ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml HARAPRASAD MALIK 9.9 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8.5							
2023 PM ml Ns 2 ml BECHAN SAHA 8.4 10 2023 PM ml Ns 2 ml BECHAN SAHA 8.4 11 10-02- 10:00:00 DIALUTED IN 100 2 ml HARAPRASAD 9.9 11 2023 AM ml Ns 2 ml HARAPRASAD 9.9 12 10-02- 06:00:00 DIALUTED IN 100 2 ml ABEDA BIBI 9.1 12 10-02- 06:00:00 DIALUTED IN 100 2 ml ABEDA BIBI 9.1 13 12-02- 10:00:00 DIALUTED IN 100 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 2 ml BHARAT TURI 8 5	9				2 ml SEKHAR MAJH	SEKHAR MAJHI	7.8
10 10 10 10 10 10 10 10 10 10 10 10 10 10 11 10 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>							
2023 PM ml Ns PM PM pm Ns PM	10	09-02-	02:00:00	DIALUTED IN 100	2 ml	BECHAN SAHA	84
11 2023 AM ml Ns 2 ml MALIK 9.9 12 10-02- 06:00:00 DIALUTED IN 100 2 ml ABEDA BIBI 9.1 12 2023 PM ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 10:00:00 DIALUTED IN 100 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 2 ml BHABAT TUBI 8.5	10	2023	PM	ml Ns	2 111	Deemaa	0.4
2023 AM ml Ns MALIK 12 10-02- 2023 06:00:00 DIALUTED IN 100 ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 2023 10:00:00 DIALUTED IN 100 ml Ns 2 ml SMRITI DHALI 8 14 12-02- 12-02- 02:30:00 DIALUTED IN 100 DIALUTED IN 100 2 ml BHARAT TURI 8 5	11	10-02-	10:00:00	DIALUTED IN 100	2 ml	HARAPRASAD	00
12 2023 PM ml Ns 2 ml ABEDA BIBI 9.1 13 12-02- 10:00:00 DIALUTED IN 100 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 2 ml BHARAT TURI 8 5	11	2023	AM	ml Ns	2 111	MALIK).)
2023 PM ml Ns ml	12	10-02-	06:00:00	DIALUTED IN 100	2 ml	AREDA RIRI	0 1
13 2023 AM ml Ns 2 ml SMRITI DHALI 8 14 12-02- 02:30:00 DIALUTED IN 100 2 ml BHARAT TURI 8 5	14	2023	PM	ml Ns	<i>2</i> IIII	ADĽDA DIDI	7.1
2023 AM ml Ns ml Ns 14 12-02- 02:30:00 DIALUTED IN 100 2 ml BHARAT TURI 8 5	12	12-02-	10:00:00	DIALUTED IN 100	2 ml	SMDITI DUATI	Q
14 2 ml BHARAT TURI 85	13	2023	AM	ml Ns	<i>4</i> 1111	ΟΝΙΚΙ Η υπΑLI	o
14 2023 PM ml Ns 2 mi BHARATTURI 8.5	14	12-02-	02:30:00	DIALUTED IN 100	2 ml	ΔΙΙΑ D Α Τ ΤΙΙΒΙ	0 5
	14	2023	PM	ml Ns	2 mi	DHAKAI IUKI	ð.5



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

15	12-02-	06:00:00	DIALUTED IN 100	2 ml	ASHIM KR.	8.9
15	2023	PM	ml Ns	2 1111	GHOSH	0.7
16	14-02-	10:00:00	DIALUTED IN 100	2 ml	SUMAN SARKAR	8.3
10	2023	PM	ml Ns	2 1111	SUMAN SAKKAK	0.3
17	15-02-	02:00:00	DIALUTED IN 100	21	SKBARI	0.2
17	2023	PM	ml Ns	2 ml	KHATOON	9.2
10	18-02-	02:00:00	DIALUTED IN 100	2 1		0.2
18	2023	PM	ml Ns	2 ml	SEKHAR MAJHI	9.2
19	20-02-	02:00:00	DIALUTED IN 100	2 ml	SUDDATA DOV	8.4
19	2023	PM	ml Ns	2 1111	SUBRATA ROY	0.4
20	22-02-	09:45:00	DIALUTED IN 100	2 ml	LALU GHOSH	7.9
20	2023	AM	ml Ns	2 1111	LALU GHUSH	1.9
21	24-02-	06:00:00	DIALUTED IN 100	2 ml	CHAMPA DAS	7.4
21	2023	PM	ml Ns	2 1111	CHANIFA DAS	/.4
22	01-03-	10:00:00	DIALUTED IN 100	2 ml		8.1
	2023	AM	ml Ns	2 1111		0.1
22	10-03-	10:00:00	DIALUTED IN 100	2 ml	SOMNATH CHOSH	7.5
23	2023	AM	ml Ns	2 1111	SOMINATH GHUSH	1.5
24	15-03-	02:00:00	DIALUTED IN 100	2 ml	CADUAN MANDI	8
24	2023	PM	ml Ns	<i>4</i> IIII	SAURAN WANDI	o
25	25-03-	06:00:00	DIALUTED IN 100	2 ml	CADANA DECUM	7.0
23	2023	AM	ml Ns	2 mi	SADANA BEGUNI	7.9
22 23 24 25	2023 10-03- 2023 15-03- 2023 25-03- 2023	AM 10:00:00 AM 02:00:00 PM 06:00:00	ml Ns DIALUTED IN 100 ml Ns DIALUTED IN 100 ml Ns DIALUTED IN 100 ml Ns	2 ml 2 ml 2 ml 2 ml	NIDHI KUMARISOMNATH GHOSHSADHAN MANDISABANA BEGUM	7.

Table 3: Patient details of Location 3 (ID & BG, West Bengal)

SL. NO.	DATE	TIME	PROCESS OF DOSAGE	AMOUN T OF FCM	PATIENT'S NAME	Hb
6	16-02- 2023	02:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	ASTO MONDAL	7.5
1	17-02- 2023	10:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	JAYDUL SAHA	8.5
12	17-02- 2023	10:00:00 AM	DIALUTED IN 100 ml Ns	2 ml	GOPAL GUPTA	9
9	18-02- 2023	02:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	MADAN PRASAD SHAH	8.9
7	18-02- 2023	06:15:00 PM	DIALUTED IN 100 ml Ns	2 ml	PROTIMA KOLEY	9.9
17	20-02- 2023	02:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	MITHU RAY	7
20	21-02- 2023	06:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	TARUN DAS	8.5



E-ISSN: 2582-2160 • Website: www.ijfmr.com

• Email: editor@ijfmr.com

	22-02-	02:00:00	DIALUTED IN 100		1	I
14	2023	02:00:00 PM	ml Ns	2 ml	DANESWAR BAG	7.8
	2023	09:45:00	DIALUTED IN 100			
5	27-02- 2023	09.45.00 AM	ml Ns	2 ml	HABEE ORANG	8
	2023	06:00:00	DIALUTED IN 100			
23	2023	PM	ml Ns	2 ml	AMAL ADHIKARY	8.6
	01-03-	02:00:00	DIALUTED IN 100		SOMNATH	
3	2023	PM	ml Ns	2 ml	CHATTERJEE	7.9
	02-03-	06:00:00	DIALUTED IN 100			
11	2023	AM	ml Ns	2 ml	SUPARNA GHOSH	7.8
0	02-03-	02:30:00	DIALUTED IN 100	• •		
8	2023	PM	ml Ns	2 ml	ALOKA DAS	8.4
10	03-03-	02:00:00	DIALUTED IN 100	2		
18	2023	PM	ml Ns	2 ml	DEBNATH DHARA	7.4
22	04-03-	02:00:00	DIALUTED IN 100	2 ml	TANMAY BARMAN	7
	2023	PM	ml Ns	2 1111		/
15	06-03-	10:00:00	DIALUTED IN 100	2 ml	ALPANA PRAMANIK	7.9
13	2023	PM	ml Ns	2 1111		1.5
25	08-03-	10:00:00	DIALUTED IN 100	2 ml	KUSUM DEVI	8.7
20	2023	AM	ml Ns	2 111	KOSOM DE VI	0.7
21	12-03-	09:45:00	DIALUTED IN 100	2 ml	SOMA DOLUI	8.4
	2023	AM	ml Ns	2 111	Soundboller	0.1
24	13-03-	06:00:00	DIALUTED IN 100	2 ml	PARTHA KOLEY	9.5
	2023	AM	ml Ns			7.5
10	13-03-	06:00:00	DIALUTED IN 100	2 ml	BABLU ORANG	8.3
	2023	PM	ml Ns			
16	15-03-	12:00:00	DIALUTED IN 100	2 ml	DILIP DAS	7.5
	2023	AM	ml Ns			
2	17-03-	10:00:00	DIALUTED IN 100	2 ml	RATAN DAS	8
	2023	AM	ml Ns			
13	19-03- 2023	12:00:00	DIALUTED IN 100	2 ml	KRISHNA MURARI BADMAN	9.1
	2023 20-03-	AM 06:00:00	ml Ns		BARMAN	
4	20-03-2023	06:00:00 PM	DIALUTED IN 100 ml Ns	2 ml	DIPU DEY	9.2
	2023	02:00:00	DIALUTED IN 100			
19	22-03-2023	02:00:00 PM	ml Ns	2 ml	SUJIT KR TALUKDAR	9.7
			ient details of Location			

 Table 4: Patient details of Location 4 (Howrah, West Bengal)

2.3. Treatment characteristics

The cumulative FCM dosage for iron repletion was calculated considering both the patient's body weight and haemoglobin level. As an integral component of the standard care protocol, FCM 500/1K (manufactured by Eskag Pharma Pvt. Ltd., Kolkata, India) was administered intravenously, with each infusion not surpassing 1000 mg of iron.



Body Weight	Cumulative FCM Dose Hb <10 g/dL	Cumulative FCM Dose Hb 10–14 g/dL
<35 kg	500 mg	500 mg
35 kg to <70 kg	1500 mg	1000 mg
≥70 kg	2000 mg	1500 mg

Table 5: Cumulative FCM Dosage for Iron Repletion

2.4. Outcome Measures and Statistical Analysis

Patient data were sourced from their medical records. These records were then anonymized and meticulously documented by trained technicians using designated case record forms (CRF) tailored for the study. Additionally, the clinical opinions of physicians regarding the efficacy and safety of ferric carboxymaltose (FCM) were also recorded in the CRF. The evaluation of efficacy was conducted through a clinical assessment, considering both symptomatic and hematological improvements as documented in the medical records.³ Safety assessments were based on the scrutiny of adverse events and side effects associated with FCM, all of which were documented in the patients' medical records.

3. Results

3.1. Efficacy outcomes

In the study population, noticeable improvements in various haematological parameters were observed after 4 weeks, demonstrating statistical significance (P < 0.001 for all). Specifically, haemoglobin (Hb) levels exhibited a substantial increase of 3.292 g/dL, while serum ferritin levels rose by 36.65 μ g/L. Additionally, there were significant enhancements in red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), and mean corpuscular haemoglobin (MCH). Although a positive trend was noted, the increase in mean corpuscular haemoglobin concentration (MCHC) at 4 weeks compared to baseline did not reach statistical significance (P = 0.103). These findings underscore the effectiveness of the intervention in fostering improvements across a spectrum of haematological indicators, with particular emphasis on Hb levels, RBC characteristics, and iron stores.

Parameter	At Baseline (Mean ± SD)	At 4 Weeks (Mean ± SD)	Mean Improvement ± SD
Haemoglobin (g/dL)	8.34	11.632	2.327796
Ferritin (µg/L)	40.20	76.85	36.65
RBC (mn/mm ³)	4	4.80	0.80
Haematocrit (%)	30.20	35.50	5.30
MCV (fL)	69	77.2	8.2
MCH (pg)	26	29	3
MCHC (g/dL)	28.5	35.8	7.3

 Table 6: Comparing Haematological Parameters Before and After Administration of FCM



E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u> • Email: editor@ijfmr.com

3.2. Safety

The commonly documented adverse effects associated with ferric carboxymaltose (FCM) administration, such as nausea, headache, constipation, diarrhea, and allergic reactions, were notably absent in the present study.⁴ Strikingly, no adverse events, especially anaphylactic shock, were reported among the patients following FCM administration, resulting in a remarkable low rate of adverse events in the study, with 0% anaphylactic shock experienced by the patients (In the following images, value 1 depicts no adverse events). Previous studies have reported a high rate of anaphylaxis reaction after FCM injection.⁵ The present study proves potentiality and safety of Eskag sponsored FCM injection in this regard, with 0% rate of anaphylactic shock in the patients. This observation holds significance, particularly in the context of the study being sponsored by Eskag Pharma and involving the use of FCM injection. The absence of adverse effects underscores the potential safety profile and tolerability of FCM in the studied population.




Table 7: Pre-and-post FCM administration vitals of patients in Location 1 (Basirhat, West Bengal)




 Table 8: Pre-and-post FCM administration vitals of patients in Location 2 (Behala, West Bengal)




 Table 9: Pre-and-post FCM administration vitals of patients in Location 3 (ID & BG, West Bengal)

E-ISSN: 2582-2160 • Website: <u>www.ijfmr.com</u>

Email: editor@ijfmr.com




Table 10: Pre-and-post FCM administration vitals of patients in Location 4 (Howrah, WestBengal)

4. Discussion

Expert consensus regarding the use of ferric carboxymaltose (FCM) in treating iron deficiency anaemia (IDA) underscores compelling evidence supporting both its efficacy and safety across various acute and chronic conditions. A comprehensive systematic review and network meta-analysis of 21 randomised controlled trials demonstrated significant improvements in serum ferritin levels (μ g/L) with FCM compared to oral iron (Δ 172.8; 95% confidence interval [CI] 66.7–234.4). Furthermore, haemoglobin (Hb) levels (g/dL) showed significant improvement with FCM compared to intravenous ferric gluconate (Δ 0.6; 95% CI 0.2–0.9), oral iron (Δ 0.8; 95% CI 0.6–0.9), and placebo (Δ 2.1; 95% CI 1.2–3.0). Notably, FCM demonstrated a lower incidence of side effects compared to other parenteral therapies.

Despite a scarcity of real-world studies on FCM, particularly from India, existing evidence suggests that haematological parameters in patients with moderate-to-severe IDA exhibit improvement within 6 to 12 weeks following intravenous (IV) iron supplementation. Oral iron supplementation, however, requires a more extended period for normalization. In contrast, Hb levels may significantly improve within two to four weeks of IV FCM supplementation, as evident in our study where Hb improvement was significant at week 4 across the entire study population, regardless of IDA severity.

A positive response to iron therapy, manifested by improved haematological parameters, serves as a reliable indicator of IDA. While Hb and ferritin are commonly used measures, their assessment can be influenced by various factors. Thus, evaluating a comprehensive array of haematological parameters provides a more thorough assessment of therapy response. In patients with hemodynamically stable IDA, FCM enables the rapid administration of high iron doses with low immunogenicity. Importantly, the observed improvements in Hb and ferritin levels are sustained for up to six months following a single IV infusion, aligning with the findings in our study, which demonstrated significant improvements in Hb, serum ferritin, RBC count, haematocrit, and MCH in subjects with severe IDA (P < 0.001 for all).

5. Conclusion

In conclusion, this study investigated the efficacy and safety of ferric carboxymaltose (FCM) in the treatment of iron deficiency anaemia (IDA) in a cohort of 100 patients across four locations in West Bengal, India. The results demonstrated significant improvements in various hematological parameters, including a substantial increase in haemoglobin levels, following FCM administration. The study also highlighted the absence of adverse events, showcasing a favorable safety profile of FCM in this population.



The use of FCM, a third-generation parenteral iron formulation, proved effective in addressing moderateto-severe IDA, aligning with existing evidence supporting its efficacy and safety. The rapid and substantial improvement in haemoglobin levels observed within four weeks of FCM administration emphasizes its efficiency in iron repletion, particularly in cases where oral preparations may be insufficient. The absence of adverse effects further supports the tolerability of FCM, a crucial factor in its consideration for widespread use.

The study contributes valuable real-world data, especially in the context of the high prevalence of anaemia in India. The findings underscore the potential of FCM as a cornerstone in the treatment of severe anaemia, advocating for its inclusion in targeted interventions and public health initiatives. Overall, this study adds to the growing body of evidence supporting FCM as a promising option in the management of iron deficiency anaemia.

References

- Charmila A, Natarajan S, Chitra TV, Pawar N, Kinjawadekar S, Firke Y, Murugesan U, Yadav P, Ohri N, Modgil V, Rodge A, Swami OC. Efficacy and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia: A Multi-Center Real-World Study from India. J Blood Med. 2022 Jun 8;13:303-313. doi: 10.2147/JBM.S361210. PMID: 35706850; PMCID: PMC9189149.
- Wajid, R.A.B.I.A., Gondal, M.E.H.N.A.Z., Tahira, T., Maqbool, S.A.D.A.F., Kausar, R. and Khalil, N.A.Z.I.A., 2021. Comparison of Efficacy and Safety of Ferric Carboxymaltose Injection with IV Iron Sucrose Complex for Correction of Postpartum Iron Deficiency Anemia. *Pak. J Med Health Sci*, 15, pp.826-9.
- Naqash A, Ara R, Bader GN. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. BMC Womens Health. 2018 Jan 5;18(1):6. doi: 10.1186/s12905-017-0506-8. PMID: 29304848; PMCID: PMC5755312.
- 4. Bhat, V., Kiran, B., Deshmukh, G., Kulkarni, K. and Rodge, A., 2021. Efficacy and safety of ferric carboxymaltose in Indian pregnant women with iron deficiency anemia. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology*, *10*(12), pp.4402-4407.
- Arici AM, Kumral Z, Gelal A, Akdeniz B. Fatal anaphylactic reaction due to ferric carboxymaltose: A case report. Anatol J Cardiol. 2020 Aug;24(2):115-117. doi: 10.14744/AnatolJCardiol.2020.38996. PMID: 32749249; PMCID: PMC7460686.